We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Targeting DNA methylation
- Epigenetics in cancer
- Hallmarks of cancer altered by methylation
- Knudson's two-hit hypothesis
- Secondary cancers from chemotherapy
- DNA methylation, decitabine, and azacitidine
- How DNA methyltransferase inhibitors work?
- Muscle differentiation induced by 5-azacytidine
- Maintenance of DNA methylation
- Inhibition of methylation vs. cytotoxicity
- Azacitidine vs. decitabine
- Vidaza (azacitidine) and Dacogen (decitabine)
- Hypomethylating agents and hydroxyurea
- Hydroxyurea effect
- Aphidicolin effect
- Cytidine analogs
- Clinical experience of azacitidine and decitabine
- Induction of epigenetic changes by 5-azacytidine
- Clinical results of low dose decitabine
- Azacitidine survival study
- Overall survival: azacitidine vs. CCR
- DNMTi in solid tumors
- Azacitidine in solid tumors
- Identifying the target
- How do you measure DNA methylation?
- Surrogate for global DNA methylation
- Decitabine treatment in CML patient
- Decitabine: methylation and clinical response
- Decitabine: methylation dose response
- Phase 1 clinical study of azacitidine
- Treatment schema
- Results: LINE-1 DNA methylation changes
- DNA repetitive elements serve as a surrogate
- Summary of clinical translational data
- Identifying specific gene targets
- Targets of DNA methylation in cancer
- Illumina analysis of APL, CML and GIST
- CML and APL hypermethylated genes algorithms
- ABL methylation is specific to CML patients
- ID4 methylation and cancer progression
- DNA methylation in CML
- Genes involved in CML progression
- Next generation epigenomic technology
- Azacitidine treatment of MDS: methylation
- The role of the Philadelphia chromosome
- Next generation DNMTi
- Degradation of 5-aza-nucleosides
- What's next?
- 5-aza-2'-deoxycytidine and S110
- Incorporation of azacytosine into a oligonucleotide
- Capecitabine (Xeloda)
- Reactivation of GFP is dependent upon CES1
- Summary
- Acknowledgements
Topics Covered
- DNA Methylation as a target for disease therapy
- Azacitidine and Decitabine are "mechanistic" inhibitors of DNA methylation
- Clinical experience with DNA methylation inhibitors
- Translational science of biomarkers for DNA methylation inhibitor therapy
- Next generation drugs to inhibit DNA methylation
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Yang, A. (2010, July 1). Reversing DNA methylation pharmacologically [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/NOYH8098.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Allen Yang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.